

Special Issue

Viruses and Endothelial Dysfunction

Message from the Guest Editor

The introduction of cART, has considerably decreased the viral burden and opportunistic infections and increased the life expectancy in HIV+-infected people. Conversely, HIV+ individuals develop a greater vulnerability to non-AIDS-related complications. In particular, HIV+ patients have a higher risk of developing endothelial dysfunction, which may occur in both the absence and presence of suppressive cART. HIV-1-encoded proteins are expressed in HIV+ individuals, even in the absence of viral replication, and are able to induce strong changes in endothelial cell (EC) physiology and morphology, to induce direct EC damage and to develop an inflammatory microenvironment. As a consequence, viral proteins may represent some of the essential factors involved in the development of endothelial disorders in AIDS. Understanding the key role of some HIV-1 protein in sustaining EC aberrant functioning may help in identifying new therapeutic approaches for combating and preventing HIV-1-related vascular diseases. All researchers working in the field are cordially invited to contribute original research papers or propose reviews to feature in this Special Issue.

Guest Editor

Prof. Dr. Francesca Caccuri
Department of Molecular and Translational Medicine, University of
Brescia, 25123 Brescia, Italy

Deadline for manuscript submissions

closed (1 July 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/40294

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).